{"id":"https://openalex.org/W2979947481","doi":"https://doi.org/10.1182/blood.v126.23.1683.1683","title":"Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)","display_name":"Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)","publication_year":2015,"publication_date":"2015-12-03","ids":{"openalex":"https://openalex.org/W2979947481","doi":"https://doi.org/10.1182/blood.v126.23.1683.1683","mag":"2979947481"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v126.23.1683.1683","doi":"https://doi.org/10.1182/blood.v126.23.1683.1683","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v126.23.1683.1683","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049400849","display_name":"Michael Robert Savona","orcid":"https://orcid.org/0000-0003-3763-5504","observed_orcids":["https://orcid.org/0000-0003-3763-5504"]},"institutions":[{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]},{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael R. Savona","raw_affiliation_strings":["Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN","institution_ids":["https://openalex.org/I4390039299","https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060015628","display_name":"Olatoyosi M. Odenike","orcid":"https://orcid.org/0000-0002-4027-4124","observed_orcids":["https://orcid.org/0000-0002-4027-4124"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Olatoyosi Odenike","raw_affiliation_strings":["University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009091754","display_name":"Philip C. Amrein","orcid":"https://orcid.org/0000-0001-7770-2623","observed_orcids":["https://orcid.org/0000-0001-7770-2623"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philip C. Amrein","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090527595","display_name":"David P. Steensma","orcid":"https://orcid.org/0000-0001-5130-9284","observed_orcids":["https://orcid.org/0000-0001-5130-9284"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David P. Steensma","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110967040","display_name":"Wael A. Harb","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131576","display_name":"Horizon Oncology Center","ror":"https://ror.org/03ambf510","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210131576"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wael A. Harb","raw_affiliation_strings":["Horizon Oncology Center, Lafayette, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Horizon Oncology Center, Lafayette, IN","institution_ids":["https://openalex.org/I4210131576"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035609080","display_name":"Amy Elizabeth Dezern","orcid":"https://orcid.org/0000-0001-5225-4609","observed_orcids":["https://orcid.org/0000-0001-5225-4609"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I4210150714","display_name":"Johns Hopkins Hospital","ror":"https://ror.org/05cb1k848","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210150714"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy E. DeZern","raw_affiliation_strings":["Johns Hopkins University Hospital, Baltimore, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johns Hopkins University Hospital, Baltimore, MD","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I4210150714"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022002706","display_name":"Laura Christian Michaelis","orcid":"https://orcid.org/0000-0002-1798-9658","observed_orcids":["https://orcid.org/0000-0002-1798-9658"]},"institutions":[{"id":"https://openalex.org/I204308271","display_name":"Medical College of Wisconsin","ror":"https://ror.org/00qqv6244","country_code":"US","type":"education","lineage":["https://openalex.org/I204308271"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura C. Michaelis","raw_affiliation_strings":["Medical College of Wisconsin, Milwaukee, WI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical College of Wisconsin, Milwaukee, WI","institution_ids":["https://openalex.org/I204308271"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046097970","display_name":"Stefan H Faderl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Stefan Faderl","raw_affiliation_strings":["Hackensack University Medical Center, Hackensack, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hackensack University Medical Center, Hackensack, NJ","institution_ids":["https://openalex.org/I1324520350"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008299243","display_name":"James N. Lowder","orcid":"https://orcid.org/0000-0003-4267-5447","observed_orcids":["https://orcid.org/0000-0003-4267-5447"]},"institutions":[{"id":"https://openalex.org/I4387155454","display_name":"Astex Pharmaceuticals","ror":"https://ror.org/05fx1fs38","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4387155454"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"James N. Lowder","raw_affiliation_strings":["Astex Pharmaceuticals, Inc., Pleasanton, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Inc., Pleasanton, CA","institution_ids":["https://openalex.org/I4387155454"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018689852","display_name":"Pietro Taverna","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155454","display_name":"Astex Pharmaceuticals","ror":"https://ror.org/05fx1fs38","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4387155454"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Pietro Taverna","raw_affiliation_strings":["Astex Pharmaceuticals, Inc., Pleasanton, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Inc., Pleasanton, CA","institution_ids":["https://openalex.org/I4387155454"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001745177","display_name":"Aram Oganesian","orcid":"https://orcid.org/0000-0001-5358-743X","observed_orcids":["https://orcid.org/0000-0001-5358-743X"]},"institutions":[{"id":"https://openalex.org/I4387155454","display_name":"Astex Pharmaceuticals","ror":"https://ror.org/05fx1fs38","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4387155454"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Aram Oganesian","raw_affiliation_strings":["Astex Pharmaceuticals, Inc., Pleasanton, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Inc., Pleasanton, CA","institution_ids":["https://openalex.org/I4387155454"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039253772","display_name":"Richa Dua","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155454","display_name":"Astex Pharmaceuticals","ror":"https://ror.org/05fx1fs38","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4387155454"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Richa Dua","raw_affiliation_strings":["Astex Pharmaceuticals, Inc., Pleasanton, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Inc., Pleasanton, CA","institution_ids":["https://openalex.org/I4387155454"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011283019","display_name":"Roya Nawabi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155454","display_name":"Astex Pharmaceuticals","ror":"https://ror.org/05fx1fs38","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4387155454"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Roya Nawabi","raw_affiliation_strings":["Astex Pharmaceuticals, Inc., Pleasanton, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Inc., Pleasanton, CA","institution_ids":["https://openalex.org/I4387155454"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019816977","display_name":"Mohammad Azab","orcid":"https://orcid.org/0009-0001-8837-6613","observed_orcids":["https://orcid.org/0009-0001-8837-6613"]},"institutions":[{"id":"https://openalex.org/I4387155454","display_name":"Astex Pharmaceuticals","ror":"https://ror.org/05fx1fs38","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4387155454"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mohammad Azab","raw_affiliation_strings":["Astex Pharmaceuticals, Inc., Pleasanton, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astex Pharmaceuticals, Inc., Pleasanton, CA","institution_ids":["https://openalex.org/I4387155454"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5061026876","display_name":"Guillermo Garcia\u2010Manero","orcid":"https://orcid.org/0000-0002-3631-2482","observed_orcids":["https://orcid.org/0000-0002-3631-2482"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guillermo Garcia-Manero","raw_affiliation_strings":["The University of Texas M.D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas M.D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":12,"corresponding_author_ids":["https://openalex.org/A5001745177","https://openalex.org/A5008299243","https://openalex.org/A5011283019","https://openalex.org/A5018689852","https://openalex.org/A5039253772","https://openalex.org/A5046097970"],"corresponding_institution_ids":["https://openalex.org/I1324520350","https://openalex.org/I4387155454"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":1.3021,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.83082388,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"126","issue":"23","first_page":"1683","last_page":"1683"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.885699987411499,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.885699987411499,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.008899999782443047,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.006800000090152025,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/astx727","display_name":"ASTX727","score":0.9829999804496765},{"id":"https://openalex.org/keywords/decitabine","display_name":"decitabine","score":0.9129999876022339},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9210000038146973},{"id":"https://openalex.org/keywords/chronic-myelomonocytic-leukemia","display_name":"chronic myelomonocytic leukemia","score":0.9539999961853027},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6539999842643738},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.8489999771118164},{"id":"https://openalex.org/keywords/line-1-methylation","display_name":"LINE-1 methylation","score":0.878000020980835},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.6830000281333923},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.6110000014305115},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.4050000011920929},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.4819999933242798},{"id":"https://openalex.org/keywords/azacitidine","display_name":"azacitidine","score":0.5149999856948853}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8359295129776001},{"id":"https://openalex.org/C2780235182","wikidata":"https://www.wikidata.org/wiki/Q1181878","display_name":"Decitabine","level":5,"score":0.772939145565033},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6821495890617371},{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.6222782135009766},{"id":"https://openalex.org/C2776985229","wikidata":"https://www.wikidata.org/wiki/Q18021211","display_name":"Cytidine deaminase","level":3,"score":0.5963451862335205},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5889999270439148},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.550662100315094},{"id":"https://openalex.org/C2777928532","wikidata":"https://www.wikidata.org/wiki/Q1088072","display_name":"Chronic myelomonocytic leukemia","level":4,"score":0.511707067489624},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4895423352718353},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.47121065855026245},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.45219454169273376},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.4459741413593292},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4255814552307129},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.40598633885383606},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.20030337572097778},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.08686473965644836},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.0},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v126.23.1683.1683","doi":"https://doi.org/10.1182/blood.v126.23.1683.1683","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v126.23.1683.1683","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2587592231","https://openalex.org/W3123807920","https://openalex.org/W2986575254","https://openalex.org/W4310159419","https://openalex.org/W4389234373","https://openalex.org/W606465697","https://openalex.org/W3096384900","https://openalex.org/W3154119140","https://openalex.org/W4405044528","https://openalex.org/W2740398835"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"Patients":[2],"with":[3,19,24,42,72,108,143,159,236,346,403,661,675],"International":[4,322],"Prognostic":[5],"Scoring":[6],"System":[7],"(IPSS)":[8],"intermediate":[9],"(Int)":[10],"and":[11,29,65,99,138,274,282,305,364,412,476,481,485,536,581,590,612,623,657,701,726,740,744,760,764],"high":[12],"risk":[13],"(HR)":[14],"MDS":[15,147,725],"benefit":[16],"from":[17,367,538],"therapy":[18],"hypomethylating":[20],"agents":[21],"(HMAs).":[22],"Treatment":[23],"the":[25,97,119,167,170,172,195,202,243,291,321,339,419,462,572,630,651],"HMAs":[26],"decitabine":[27],"(DAC)":[28],"azacitidine":[30],"(AZA)":[31],"requires":[32],"5":[33,593,685],"or":[34,145,148,313,549,639,723,780,793,815,826,837,848,878,890,901],"7":[35],"daily":[36],"parenteral":[37],"doses":[38,74,307,405,652,697],"respectively":[39,493],"every":[40],"month":[41],"some":[43],"patients":[44,142,277,380,586],"remaining":[45],"on":[46,215,226,239,276,459,478,487,520,527,588,774,787,809,820,831,842,872,884,895],"treatment":[47,70],"for":[48,285,311,327,439,540,684,746,766],"extended":[49,69],"periods.":[50],"An":[51],"orally":[52,106],"administered":[53,377,627],"HMA":[54],"would":[55],"provide":[56],"significant":[57],"patient":[58,206],"convenience,":[59],"potentially":[60],"enhance":[61],"adherence":[62],"to":[63,88,165,177,188,378,425,571,704,716],"treatment,":[64],"may":[66],"allow":[67],"exploring":[68],"schedules":[71],"lower":[73,696],"of":[75,124,131,135,169,182,198,212,246,288,338,343,400,406,453,468,569,620,634,653,698,778,791,813,824,835,846,876,888,899],"DAC.":[76],"Neither":[77],"DAC":[78,137,183,193,210,398,421,441,464,470,495,508,622,645,656,680,700,715,732,736,752,756],"nor":[79],"AZA":[80],"is":[81,105,673],"readily":[82],"bioavailable":[83,107],"in":[84,96,113,155,253,263,278,302,490,517,558,670,719],"oral":[85,136,185,224,237,306,397,407,420,457,499,512,621,624,699,717,741,761],"form":[86],"due":[87],"rapid":[89],"clearance":[90],"by":[91,191,223,230,259,708],"cytidine":[92],"deaminase":[93],"(CDA)":[94],"present":[95],"gut":[98],"liver.":[100],"E7727,":[101],"a":[102,109,125,160,179,298,395,449],"novel":[103],"CDAi,":[104],"large":[110],"safety":[111,168,268,664],"margin":[112],"preclinical":[114],"models.":[115],"We":[116],"report":[117],"here":[118],"first":[120,203],"Phase":[121,335],"1":[122,217,336,437,529,602,606,609],"results":[123],"PK-guided":[126],"FIH":[127],"dose":[128,197,211,245,399,422,705],"escalation":[129],"trial":[130,158,340,693],"ASTX727":[132,186,225,238,289,391,458,500,513,617,718,742,762],"(the":[133,618],"combination":[134,619],"E7727).":[139],"Methods:":[140],"Adult":[141],"Int":[144,722],"HR":[146,724],"Chronic":[149],"Myelomonocytic":[150],"Leukemia":[151],"(CMML)":[152],"were":[153,234,250,257,308,318,362,376,556,574],"enrolled":[154],"this":[156],"dose-escalating":[157],"3+3":[161],"design.":[162],"In":[163,201,388,416],"addition":[164],"assessing":[166],"combination,":[171],"primary":[173,631],"PK":[174,273,632],"objective":[175,598,633],"was":[176,300,355,369,392,423,430,472,501,532],"achieve":[178],"mean":[180,450,463],"AUC":[181,438,465,471,496,648,733,753],"following":[184,679],"comparable":[187],"that":[189,676],"achieved":[190,629],"IV":[192,209,440,469,515,644,683,714,735,755],"at":[194,242,290,297,409,432,591,650],"approved":[196],"20":[199,213,401,442,646,681,737,757],"mg/m2.":[200],"cycle,":[204],"each":[205,279,286,303,349],"received":[207,385],"an":[208,219,662,775,788,810,821,832,843,873,885,896],"mg/m2":[214,443,647,682,738,758],"Day":[216,436,479,488,521,530,637,642,666],"as":[218,394,466],"internal":[220],"comparator":[221],"followed":[222,707],"Days":[227,240,460],"2-5":[228],"escalated":[229,301,424],"cohort.":[231,293],"Subsequent":[232],"cycles":[233],"given":[235,393],"1-5":[241],"same":[244],"Cycle":[247],"1.":[248,730,750],"Cycles":[249],"28":[251],"days":[252,371],"length.":[254],"Pharmacodynamics":[255],"(PD)":[256],"evaluated":[258,271],"LINE-1":[260,525,668],"DNA":[261],"methylation":[262],"peripheral":[264],"blood.":[265],"A":[266],"data":[267],"review":[269],"committee":[270],"safety,":[272],"PD":[275],"completed":[280,341],"cohort":[281,304,417],"determined":[283],"dosing":[284,342],"component":[287,296],"next":[292],"Only":[294],"one":[295],"time":[299,366],"not":[309],"adjusted":[310],"weight":[312],"body":[314],"surface":[315],"area.":[316],"Responses":[317],"assessed":[319],"using":[320],"Working":[323],"Group":[324],"(IWG)":[325],"criteria":[326],"response":[328],"(Cheson":[329],"et":[330],"al,":[331],"2006).":[332],"Results:":[333],"The":[334,352,435,561,692],"portion":[337,712],"4":[344,446,506,519,672],"cohorts":[345,389,447,491,541,747,767],"6":[347],"subjects":[348],"(24":[350],"subjects).":[351],"median":[353,365],"age":[354],"71":[356],"years":[357],"(range":[358,372],"59-85),":[359],"15/24":[360],"(63%)":[361],"male,":[363],"diagnosis":[368],"307":[370],"5-3024).":[373],"Prior":[374],"therapies":[375],"10":[379],"including":[381],"five":[382],"who":[383],"had":[384,448],"prior":[386],"HMA.":[387],"1-3":[390],"fixed":[396],"mg":[402,414,427,655,659],"escalating":[404],"E7727":[408,429,626,660],"40,":[410],"60,":[411],"100":[413,433,658],"respectively.":[415,543],"4,":[418],"40":[426,654],"while":[428],"kept":[431],"mg.":[434],"over":[444],"all":[445],"(SD)":[451],"value":[452],"193(82)":[454],"ng*hr/mL.":[455],"After":[456],"2-5,":[461],"%":[467,524],"17,":[473],"19,":[474],"32,":[475],"98%":[477],"2":[480,613,711],"31,":[482],"41,":[483],"58":[484],"148%":[486],"5,":[489],"1-4":[492,542,748,768],"(Figure).":[494],"variability":[497],"after":[498,511,734,754],"acceptable":[502],"(CV%":[503],"35-53":[504],"across":[505],"cohorts).":[507],"Cmax":[509],"values":[510],"approached":[514],"(87%)":[516],"Cohort":[518,671],"5.":[522],"Mean":[523,731,751],"demethylation":[526,669],"cycle":[528],"8\u00b1SE":[531],"6.8%\u00b12.7;":[533],"8.6%\u00b12.7;":[534],"9.5%\u00b13.3;":[535],"15.3%\u00b13.4":[537],"baseline":[539],"No":[544],"Dose":[545],"Limiting":[546],"Toxicities":[547],"(DLTs)":[548],"Grade":[550,564],"\u2265":[551,565],"3":[552,566],"drug-related":[553],"non-hematologic":[554],"AEs":[555,567],"observed":[557],"any":[559],"patient.":[560],"most":[562],"common":[563],"regardless":[568],"relationship":[570],"drug":[573],"thrombocytopenia":[575],"(37.5%),":[576],"anemia":[577],"(33.3%),":[578],"neutropenia":[579,583],"(29.2%)":[580],"febrile":[582],"(16.7%).":[584],"Twenty":[585],"remain":[587],"therapy,":[589],"least":[592],"so":[594],"far":[595],"have":[596,689],"experienced":[597],"clinical":[599],"responses":[600,688],"(including":[601],"Complete":[603],"Response":[604,611],"(CR),":[605],"marrow":[607],"CR,":[608],"Partial":[610],"Hematologic":[614],"Improvement).":[615],"Conclusions:":[616],"CDAi":[625],"concomitantly)":[628],"reaching":[635],"(at":[636,641],"2)":[638],"exceeding":[640],"5)":[643],"levels":[649],"excellent":[663],"profile.":[665],"8":[667],"consistent":[674],"historically":[677],"reported":[678],"days.":[686],"Clinical":[687],"been":[690],"observed.":[691],"will":[694,702],"explore":[695],"proceed":[703],"expansion":[706],"randomized":[709],"phase":[710],"comparing":[713],"previously":[720],"untreated":[721],"CMML":[727],"patients.":[728],"Figure":[729,749],"(D1)":[739,759],"(D2":[743,763],"D5)":[745,765],"Disclosures":[769],"Savona:":[770],"Karyopharm:":[771,910],"Consultancy,":[772,911,935],"Membership":[773,786,808,819,830,841,871,883,894],"entity's":[776,789,811,822,833,844,874,886,897],"Board":[777,790,812,823,834,845,875,887,898],"Directors":[779,792,814,825,836,847,877,889,900],"advisory":[781,794,816,827,838,849,879,891,902],"committees,":[782,795,850],"Research":[783,796,800,805,851,864,868,912,917,920,923,926,932,936,941],"Funding;":[784,797,801,806,865,913,918,921,924,927,933],"Incyte:":[785],"TG":[798],"Therapeutics:":[799],"Astex":[802],"Pharmaceuticals,":[803,862,944,948,952,956,960,964],"Inc:":[804],"Celgene:":[807,857,934],"committees;":[817,828,880,892,903],"Gilead:":[818],"Novartis:":[829],"committees.":[839],"Odenike:Sunesis:":[840],"Funding.":[852,869,942],"Steensma:Incyte:":[853],"Consultancy;":[854,856,858,909],"Amgen:":[855],"Onconova:":[859],"Consultancy.":[860],"Harb:Astex":[861],"Inc.:":[863,916,945,949,953,957,961,965],"Idera":[866],"Pharmaceuticals:":[867],"Michaelis:Incyte:":[870],"CTI":[881],"Biopharma:":[882],"Wyeth:":[893],"Pfizer:":[904,940],"Equity":[905],"Ownership.":[906],"Faderl:JW":[907],"Pharma:":[908],"Seattle":[914],"Genetics,":[915],"Astellas:":[919],"Celator:":[922],"Ambit:":[925],"Onyx:":[928],"Speakers":[929,938],"Bureau;":[930,939],"BMS:":[931],"Funding,":[937],"Lowder:Astex":[943],"Employment.":[946,950,954,958,962,966],"Taverna:Astex":[947],"Oganesian:Astex":[951],"Dua:Astex":[955],"Nawabi:Astex":[959],"Azab:Astex":[963]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2019-10-18T00:00:00"}